Current Gastroenterology Reports

, Volume 10, Issue 4, pp 385–390

Is irritable bowel syndrome an inflammatory disorder?

Article

Abstract

Histopathologic data demonstrate low-grade mucosal inflammation in a subset of patients with irritable bowel syndrome (IBS). This inflammatory infiltrate is mainly represented by increased numbers of T lymphocytes and mast cells lying in the lamina propria. The close apposition of immunocytes to gut nerves supplying the mucosa provides a basis for neuroimmune cross-talk, which may explain gut sensorimotor dysfunction and related symptoms in patients with IBS. A previous gastroenteritis (due to Campylobacter jejuni, Salmonella, Shigella, Escherichia coli, and, likely, viruses) is now an established etiologic factor for IBS (hence, postinfectious IBS). Other putative causes, such as undiagnosed food allergies, genetic abnormalities, stress, or bile acid malabsorption, may also promote and maintain a low-grade mucosal inflammation in IBS. The identification of mucosal inflammation in IBS has pathophysiologic implications and paves the way for novel therapeutic options.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Collins SM: The immunomodulation of enteric neuromuscular function: implications for motility and inflammatory disorders. Gastroenterology 1996, 111:1683–1699.PubMedCrossRefGoogle Scholar
  2. 2.
    Barbara G, De Giorgio R, Stanghellini V, et al.: A role for inflammation in irritable bowel syndrome? Gut 2002, 51(Suppl 1):i41–i44.PubMedCrossRefGoogle Scholar
  3. 3.
    Camilleri M: Management of the irritable bowel syndrome. Gastroenterology 2001, 120:652–668.PubMedCrossRefGoogle Scholar
  4. 4.
    De Giorgio R, Barbara G, Stanghellini V, et al.: Diagnosis and therapy of irritable bowel syndrome. Aliment Pharmacol Ther 2004, 20(Suppl 2):10–22.PubMedCrossRefGoogle Scholar
  5. 5.
    Longstreth GF, Hawkey CJ, Mayer EA, et al.: Characteristics of patients with irritable bowel syndrome recruited from three sources: implications for clinical trials. Aliment Pharmacol Ther 2001, 15:959–964.PubMedCrossRefGoogle Scholar
  6. 6.
    Longstreth GF, Thompson GW, Chey WD, et al.: Functional bowel disorders. Gastroenterology 2006, 130:1480–1491.PubMedCrossRefGoogle Scholar
  7. 7.
    Barbara G, De Giorgio R, Stanghellini V, et al.: New pathophysiological mechanisms in irritable bowel syndrome. Aliment Pharmacol Ther 2004, 20:1–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Isgar B, Harman M, Kaye MD, Whorwell PJ: Symptoms of irritable bowel syndrome in ulcerative colitis in remission. Gut 1983, 24:190–192.PubMedCrossRefGoogle Scholar
  9. 9.
    Spiller RC: Postinfectious irritable bowel syndrome. Gastroenterology 2003, 124:1662–1671.PubMedCrossRefGoogle Scholar
  10. 10.
    Barbara G, Vallance BA, Collins SM: Persistent intestinal neuromuscular dysfunction after acute nematode infection in mice. Gastroenterology 1997, 113:1224–1232.PubMedCrossRefGoogle Scholar
  11. 11.
    Barbara G, De Giorgio R, Deng Y, et al.: Role of immunologic factors and cyclooxygenase 2 in persistent postinfective enteric muscle dysfunction in mice. Gastroenterology 2001, 120:1729–1736.PubMedCrossRefGoogle Scholar
  12. 12.
    Törnblom H, Lindberg G, Nyberg B, Veress B: Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 2002, 123:1972–1979.PubMedCrossRefGoogle Scholar
  13. 13.
    Spiller RC, Jenkins D, Thornley JP, et al.: Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000, 47:804–811.PubMedCrossRefGoogle Scholar
  14. 14.
    Chadwick VS, Chen W, Shu D, et al.: Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002, 122:1778–1783.PubMedCrossRefGoogle Scholar
  15. 15.
    Dunlop SP, Jenkins D, Neal KR, et al.: Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003, 125:1651–1659.PubMedCrossRefGoogle Scholar
  16. 16.
    Dunlop SP, Jenkins D, Spiller RC: Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol 2003, 98:1578–1583.PubMedCrossRefGoogle Scholar
  17. 17.
    Salzmann JL, Peltier-Koch F, Bloch F, et al.: Morphometric study of colonic biopsies: a new method of estimating inflammatory diseases. Lab Invest 1989, 60:847–851.PubMedGoogle Scholar
  18. 18.
    Barbara G, Stanghellini V, De Giorgio R, et al.: Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004, 126:693–702.PubMedCrossRefGoogle Scholar
  19. 19.
    O’sullivan M, Clayton N, Breslin NP, et al.: Increased mast cells in the irritable bowel syndrome. Neurogastroenterol Motil 2000, 12:449–457.PubMedCrossRefGoogle Scholar
  20. 20.
    Weston AP, Biddle WL, Bhatia PS, Miner PB Jr: Terminal ileal mucosal mast cells in irritable bowel syndrome. Dig Dis Sci 1993, 38:1590–1595.PubMedCrossRefGoogle Scholar
  21. 21.
    Gwee KA, Leong YL, Graham C, et al.: The role of psychological and biological factors in postinfective gut dysfunction. Gut 1999, 44:400–406.PubMedCrossRefGoogle Scholar
  22. 22.
    Wang LH, Fang XC, Pan GZ: Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut 2004, 53:1096–1101.PubMedCrossRefGoogle Scholar
  23. 23.
    Gwee KA, Collins SM, Read NW, et al.: Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome. Gut 2003, 52:523–526.PubMedCrossRefGoogle Scholar
  24. 24.
    Liebregts T, Adam B, Bredack C, et al.: Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007, 132:913–920.PubMedCrossRefGoogle Scholar
  25. 25.
    Dinan TG, Quigley EM, Ahmed SM, et al.: Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 2006, 130:304–311.PubMedCrossRefGoogle Scholar
  26. 26.
    Coelho AM, Fioramonti J, Bueno L: Systemic lipopolysaccharide influences rectal sensitivity in rats: role of mast cells, cytokines, and vagus nerve. Am J Physiol 2000, 279:G781–G790.Google Scholar
  27. 27.
    Shah V, Lyford G, Gores G, Farrugia G: Nitric oxide in gastrointestinal health and disease. Gastroenterology 2004, 126:903–913.PubMedCrossRefGoogle Scholar
  28. 28.
    Coutinho SV, Gebhart GF: A role for spinal nitric oxide in mediating visceral hyperalgesia in the rat. Gastroenterology 1999, 116:1399–1408.PubMedCrossRefGoogle Scholar
  29. 29.
    O’sullivan M, Clayton N, Moloney G, et al.: Increased iNOS expression in irritable bowel syndrome (IBS) patients with stress related symptoms [abstract]. Gastroenterology 2003, 124:A1642.Google Scholar
  30. 30.
    Hiatt RB, Katz L: Mast cells in inflammatory conditions of the gastrointestinal tract. Am J Gastroenterol 1962, 37:541–545.PubMedGoogle Scholar
  31. 31.
    Barbara G, Wang B, Stanghellini V, et al.: Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007, 132:26–37.PubMedCrossRefGoogle Scholar
  32. 32.
    Reed DE, Barajas-Lopez C, Cottrell G, et al.: Mast cell tryptase and proteinase-activated receptor 2 induce hyper-excitability of guinea-pig submucosal neurons. J Physiol 2003, 547:531–542.PubMedCrossRefGoogle Scholar
  33. 33.
    Gao C, Liu S, Hu HZ, et al.: Serine proteases excite myenteric neurons through protease-activated receptors in guinea pig small intestine. Gastroenterology 2002, 123:1554–1564.PubMedCrossRefGoogle Scholar
  34. 34.
    Nozdrachev AD, Akoev GN, Filippova LV, et al.: Changes in afferent impulse activity of small intestine mesenteric nerves in response to antigen challenge. Neuroscience 1999, 94:1339–1342.PubMedCrossRefGoogle Scholar
  35. 35.
    Bueno L, Fioramonti J, Delvaux M, Frexinos J: Mediators and pharmacology of visceral sensitivity: from basic to clinical investigations. Gastroenterology 1997, 112:1714–1743.PubMedCrossRefGoogle Scholar
  36. 36.
    Shpacovitch V, Feld M, Bunnett NW, Steinhoff M: Protease-activated receptors: novel PARtners in innate immunity. Trends Immunol 2007, 28:541–550.PubMedCrossRefGoogle Scholar
  37. 37.
    Coelho AM, Vergnolle N, Guiard B, et al.: Proteinases and proteinase-activated receptor 2: a possible role to promote visceral hyperalgesia in rats. Gastroenterology 2002, 122:1035–1047.PubMedCrossRefGoogle Scholar
  38. 38.
    Wood JD: Enteric neuroimmunophysiology and pathophysiology. Gastroenterology 2004, 127:635–657.PubMedCrossRefGoogle Scholar
  39. 39.
    Cremon C, Gargano L, Morselli-Labate AM, et al.: Mucosal immune activation in irritable bowel syndrome is gender-dependent and associated with digestive symptoms [abstract]. Gastroenterology 2008, 134(Suppl 1):A690.Google Scholar
  40. 40.
    Schuurs AH, Verheul HA: Effects of gender and sex steroids on the immune response. J Steroid Biochem 1990, 35:157–172.PubMedCrossRefGoogle Scholar
  41. 41.
    Chang L, Heitkemper MM: Gender differences in irritable bowel syndrome. Gastroenterology 2002, 123:1686–1701.PubMedCrossRefGoogle Scholar
  42. 42.
    Spiller RC, Campbell E: Post-infectious irritable bowel syndrome. Curr Opin Gastroenterol 2006, 22:13–17.PubMedCrossRefGoogle Scholar
  43. 43.
    Marshall JK, Thabane M, Borgaonkar MR, James C: Postinfectious irritable bowel syndrome after a food-borne outbreak of acute gastroenteritis attributed to a viral pathogen. Clin Gastroenterol Hepatol 2007, 5:457–460.PubMedCrossRefGoogle Scholar
  44. 44.
    Spiller RC: Role of infection in irritable bowel syndrome. J Gastroenterol 2007, 42:41–47.PubMedCrossRefGoogle Scholar
  45. 45.
    Gonsalkorale WM, Perry C, Pravica V, et al.: Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut 2003, 52:91–93.PubMedCrossRefGoogle Scholar
  46. 46.
    O’Mahony L, McCarthy J, Kelly P, et al.: Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005, 128:541–551.PubMedCrossRefGoogle Scholar
  47. 47.
    Gonsalves N: Food allergies and eosinophilic gastrointestinal illness. Gastroenterol Clin North Am 2007, 36:75–91.PubMedCrossRefGoogle Scholar
  48. 48.
    Eutamene H, Theodorou V, Fioramonti J, Bueno L: Acute stress modulates the histamine content of mast cells in the gastrointestinal tract through interleukin-1 and corticotropin-releasing factor release in rats. J Physiol 2003, 553:959–966.PubMedCrossRefGoogle Scholar
  49. 49.
    Fukudo S, Nomura T, Hongo M: Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome. Gut 1998, 42:845–849.PubMedGoogle Scholar
  50. 50.
    Münch A, Ström M, Söderholm JD: Dihydroxy bile acids increase mucosal permeability and bacterial uptake in human colon biopsies. Scand J Gastroenterol 2007, 42:1167–1174.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Department of Internal Medicine and Gastroenterology, Building #5 (“Nuove Patologie”)St. Orsola-Malpighi HospitalBolognaItaly

Personalised recommendations